Applied Therapeutics Inc. is a biotechnology company focused on developing innovative treatments for patients with serious and chronic diseases, particularly those with unmet medical needs
The company's research emphasizes the discovery and advancement of therapeutics that target underlying disease mechanisms, with a primary focus on conditions such as diabetic complications and other metabolic disorders. Applied Therapeutics aims to leverage its expertise in chemistry and biology to bring effective solutions to the market, enhancing patient outcomes and addressing critical health challenges. Through its dedication to scientific rigor and the development of novel compounds, the company strives to make a meaningful impact in the field of medicine.
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperforming their larger-cap counterparts. However, potential for gains may be hindered by sluggish earnings and uncertain economic outlook.
Applied Therapeutics stock rises as the FDA no longer requires an Advisory Committee meeting, keeping the Priority Review on track, with the PDUFA target date set for November 28.
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised for a potential 2025 launch, analysts predict strong market performance and significant sales growth.
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.
Shares of Doma Holdings Inc. (NYSEDOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
